Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells

Chimeric antigen receptor (CAR) redirected T cells are potent therapeutic options against hematological malignancies. The current dominant manufacturing approach for CAR T cells depends on retroviral transduction. With the advent of gene editing, insertion of a CD19-CAR into the T cell receptor (TCR...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Jonas Kath, Weijie Du, Alina Pruene, Tobias Braun, Bernice Thommandru, Rolf Turk, Morgan L. Sturgeon, Gavin L. Kurgan, Leila Amini, Maik Stein, Tatiana Zittel, Stefania Martini, Lennard Ostendorf, Andreas Wilhelm, Levent Akyüz, Armin Rehm, Uta E. Höpken, Axel Pruß, Annette Künkele, Ashley M. Jacobi, Hans-Dieter Volk, Michael Schmueck-Henneresse, Renata Stripecke, Petra Reinke, Dimitrios L. Wagner
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2022-06-01
Colecção:Molecular Therapy: Methods & Clinical Development
Assuntos:
gene editing
CRISPR-Cas9
chimeric antigen receptor
non-viral cell manufacturing
CAR T cells
TRAC
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S2329050122000511
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados